Drug combo aims to control Slow-Growing lymphoma without chemo
NCT ID NCT01316523
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested a combination of two drugs, lenalidomide and rituximab, in 30 people with previously untreated indolent non-Hodgkin's lymphoma. The goal was to see how well the drugs worked together to shrink or control the cancer. Participants took lenalidomide daily for three weeks out of four, plus rituximab infusions, and the study measured how many patients responded to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide and rituximab
What this could lead to
If successful, this combination could offer a chemotherapy-free option to control indolent non-Hodgkin's lymphoma and delay the need for more aggressive treatment.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. Lenalidomide can cause serious side effects like blood clots and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sutter Pacific Medical Foundation
Santa Rosa, California, 95403, United States
-
University of California Davis Cancer Center
Sacramento, California, 95817, United States